Background: Most patients with hypertension require more than one agent to control blood pressure (BP). The purpose of this study was to assess the efficacy and safety of the angiotensin II receptor blocker olmesartan medoxomil in combination with hydrochlorothiazide (HCTZ). Methods: This was a randomized, double-blind, factorial design study. After a placebo run-in period, eligible patients (n ϭ 502) with a baseline mean seated diastolic blood pressure (SeDBP) of 100 to 115 mm Hg were randomized to one of 12 groups: placebo, olmesartan medoxomil monotherapy (10, 20, or 40 mg/day, HCTZ monotherapy (12.5 or 25 mg/day), or one of six groups of olmesartan medoxomil/HCTZ combination therapy. The primary endpoint was the change in mean trough SeDBP from baseline at week 8. Statistical analyses were conducted to determine whether at least one combination produced a larger reduction in SeDBP at week 8 than the individual corresponding component doses, but did not compare BP reductions with different combination doses.
W
ith only up to 34% of Americans with hypertension achieving a goal blood pressure (BP) of Ͻ140/90 mm Hg, more aggressive and multifaceted modes of therapy are required. [1] [2] [3] Major studies have shown that most patients with hypertension need two or more antihypertensive drugs to achieve BP control. 4 -7 Substantial evidence supports the efficacy of angiotensin II blockade using angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) to lower BP and to protect the heart and kidneys. 8 -16 Based on these data, the American Diabetes Association recommends the use of ACE inhibitors as first-line therapy for hypertensive patients with type 1 diabetic renal disease, and ARB for those with type 2 diabetes and renal disease. 17 Placebo-controlled clinical trials have shown that the BP-lowering efficacy of olmesartan medoxomil monotherapy, a long-acting, once-daily ARB, at its starting dosage (20 mg/day) and maximal dosage (40 mg/day) compares favorably with that of other antihypertensive agents such as atenolol, captopril, felodipine, and amlodipine besylate, as well as other ARBs, in clinical efficacy trials. 18 -22 Hydrochlorothiazide (HCTZ) is a thiazide diuretic that is commonly used in combination with other antihypertensive agents, including ARBs. 23, 24 Hydrochlorothiazide is known to activate the renin-angiotensin-aldosterone system (RAAS), providing a strong rationale for the combination of an ARB with HCTZ. [25] [26] [27] [28] [29] The objective of this factorial design study was to assess the efficacy and safety of olmesartan medoxomil in combination with HCTZ at various dosages compared with monotherapy with each drug and with placebo.
Methods

Study Population
This was a randomized, double-blind, factorial design study conducted at 48 investigational sites in the United States. Eligibility criteria for randomization included the following: average SeDBP Ն100 and Յ115 mm Hg at both week 3 and week 4 placebo run-in visits, with at least 4 days between the two visits; a difference of Յ7 mm Hg between the two SeDBP measurements; and at least 80% compliance with the study drug regimen during the placebo run-in period. Patients with serious medical disorders, and those with a body weight Ն50% of ideal body weight for height and frame size (calculated according to the 1983 Metropolitan Life Insurance table), were excluded. The protocol and one amendment were reviewed and approved by either a central or local institutional review board at each of the investigational sites. The study was conducted in accordance with institutional review board committee and informed consent regulations of 21 Code of Federal Regulations parts 50 and 56, and principles of the Declaration of Helsinki and its amendments. Written informed consent was obtained from each study participant at the screening visit.
Study Design
After an initial single-blind, 4-week, placebo run-in period, eligible patients (n ϭ 502) were randomized to one of 12 treatment groups for 8 weeks of double-blind treatment with placebo, olmesartan medoxomil monotherapy (at doses of 10, 20, or 40 mg/day), HCTZ monotherapy (at doses of 12.5 or 25 mg/day), or olmesartan medoxomil/ HCTZ combination therapy (including all possible combinations of doses used in the monotherapy groups). The factorial design was used to assess the efficacy and safety of olmesartan medoxomil in combination with HCTZ across a range of doses for each therapy. Patients were evaluated for therapeutic efficacy and safety on day 1 and at weeks 1, 4, and 8. Patients were instructed to take their study medication once daily in the morning with breakfast. On the day of a scheduled visit, they were instructed not to take their dose of study medication until after BP measurements were recorded and all tests were performed.
Body weight was measured at screening and at day 1. Blood pressure and heart rate were measured before the daily dose of study medication was taken on day 1 and at weeks 1, 4, and 8 (all BP measurements were to be obtained before 12 noon on the day of the scheduled study visit, and within 20 to 28 h after the previous dose of study medication). Duplicate readings were taken of seated and standing cuff BP at trough; the average of the two seated BP and the two standing BP measurements were used as the seated and standing readings, respectively, for the visit.
Safety was monitored by assessing the occurrence of adverse events (AEs) at every visit and by performing clinical laboratory tests (ie, hematology, blood chemistry, and urinalysis). All patients who were randomly assigned to study drug treatment and received at least one dose of randomized study drug were included in the safety analysis.
Efficacy Variables
The primary efficacy variable was the change from baseline in mean trough SeDBP at week 8, using the last observation carried forward (LOCF) for patients who did not complete the protocol. Secondary efficacy variables included the change from baseline in mean seated systolic blood pressure (SeSBP) at week 8 and in mean standing diastolic blood pressure (StDBP) and systolic blood pressure (StSBP) at week 8, and responder rates, defined as an SeDBP Ͻ90 mm Hg or a Ն10 mm Hg reduction in SeDBP at week 8.
Statistical Analysis
The sample size was calculated for a two-sided significance level of .05, based on the primary efficacy variable (change from baseline in mean SeDBP at week 8), to achieve 90% power for the AVE procedure proposed by Hung and colleagues. 30 Baseline and demographic characteristics were presented for each treatment group. Categorical demographic variables were summarized as percentages and compared between treatments using a 2 test. Continuous variables including baseline vital signs, age, height, weight, and duration of hypertension history were compared using one-way analysis of variance with treatment as a factor.
Criteria for antihypertensive efficacy included the following: 1) determination of whether at least one combination dose produced a larger reduction in SeDBP at week 8 than the individual corresponding component doses; 2) evaluation of which combinations were more effective in reducing BP compared with the respective placebo treatments; and 3) determination of the responder rate, defined as SeDBP Ͻ90 mm Hg or a decrease in SeDBP from baseline of Ն10 mm Hg. Changes in BP and heart rate from baseline to week 8 were compared within each dose combination group by paired t test.
The hypothesis to be tested was that none of the dose combinations were more effective than the associated component doses. The first step of the efficacy evaluation was the AVE test, 30 a test procedure based on the average of the maximum differences in response (change from baseline in SeDBP at week 8) of each combination and their corresponding components. This test was used to determine whether at least one combination existed that was more efficacious than its corresponding components. Once this was confirmed, a quadratic dose-response model was fitted to calculate the predicted dose response. A 95% CI was calculated for the treatment effect of each of the 12 groups to identify which combination was better than its individual components. Based on the fitted model, a response surface graph was generated to facilitate visual inspection of the treatment effects. Statistical analyses comparing the BP reductions obtained with different combination doses were not performed.
Safety and tolerability were assessed through the recording of clinical AEs and evaluation of clinical laboratory parameters. Summary statistics, patient listings, or both were provided for each treatment group for all safety parameters. Reasons for early withdrawal from the study were tabulated for each treatment group.
Results
A total of 863 patients were screened; of these, 750 were found eligible for enrollment, 502 were randomized, and 451 completed the study. Of the 502 patients who were randomly assigned to one of 12 treatment groups (35 to 47 patients per group), 55.6% were male and 74.1% were of white ethnicity. Mean age was 53 years, and mean baseline SeDBP and SeSBP in the 12 treatment groups ranged from 102.6 to 104.4 mm Hg and from 151.9 to 156.6 mm Hg, respectively. There were no statistically significant differences in baseline characteristics among the 12 treatment groups (Tables 1 and 2 ).
Changes in Trough Seated and Standing Blood Pressure
The raw mean SeSBP and SeDBP reductions from baseline for olmesartan medoxomil combined with HCTZ ranged from Ϫ20.5/Ϫ16.0 mm Hg to Ϫ28.3/Ϫ22.3 mm Hg. The AVE test was used to confirm the existence of at least one combination that was superior to its components. The P value corresponding to the AVE test for the week 8 SeDBP (P Ͻ .01) was smaller than the .05 critical value. Thus, at least one dose combination was more effective than its components in lowering SeDBP from baseline to week 8. Dose-related reductions in SeDBP at week 8, fitted by the quadratic model, were observed with increasing doses of olmesartan medoxomil monotherapy, HCTZ monotherapy, and olmesartan medoxomil/HCTZ combination therapy. All six olmesartan medoxomil/HCTZ combinations significantly reduced SeDBP compared with placebo (there was no overlap in the 95% CI computed from the quadratic model for each of the olmesartan medoxomil/HCTZ combination therapies and the 95% CI for placebo, ie, 0 mg olmesartan medoxomil/0 mg HCTZ; Fig.  1 and Table 2 ). The greatest reduction in SeDBP (ϳ22 mm Hg) occurred with the combination of olmesartan medoxomil/HCTZ 40/25 mg/day. Evidence of efficacy for all active treatments was observed as early as week 1 and increased throughout the course of the study.
The AVE test confirmed that at least one combination treatment produced significantly larger reductions in SeSBP than either component from baseline to week 8 (P Ͻ .01). All six olmesartan medoxomil/HCTZ combinations resulted in statistically significant reductions in SeSBP, compared with placebo, with a dose-response related to both drug components ( Fig. 2 and Table 2 ). Model fitted mean reductions in StDBP and StSBP followed patterns similar to those observed for seated BP (Table 3) .
Responder and Control Rates
The proportion of patients with BP response (trough SeDBP Ͻ90 mm Hg, or a reduction from baseline Ն10 mm Hg) for each of the 12 treatment groups at week 8 LOCF is shown in Table 4 . The highest responder rate was observed in the group assigned to olmesartan medoxomil/ HCTZ 40/25 mg/day. The proportion of patients with diastolic control (trough SeDBP Ͻ90 mm Hg) and systolic control (trough SeSBP Ͻ140 mm Hg) at week 8 LOCF is also shown in Table 4 . Although statistical analyses comparing the responder and control rates of different combinations were not performed, the highest rates were observed in the olmesartan medoxomil/HCTZ 40/25 mg/ day group.
Safety
All dosages of olmesartan medoxomil monotherapy and combination therapy with HCTZ were safe and well tolerated, with no significant or clinically relevant differences in the incidence of treatment-emergent AEs noted by dosage. The percentage of patients who experienced at least one treatment-emergent AE was 57.1% in the placebo group, 51.1% in the HCTZ monotherapy groups, 49.6% in the olmesartan medoxomil monotherapy groups, and 57.1% in the olmesartan medoxomil/HCTZ groups. Most AEs were judged to be remotely or definitely not drug related, and mild or moderate in intensity. Only one patient, who received placebo, experienced a serious AE (unstable angina).
The overall discontinuation rate due to AEs of patients who received one or both of the active study drugs was low (2.0%), and there was no apparent association between discontinuation due to an AE and dosage of any study medication, used alone or in combination. Of the three most common AEs, the incidence of dizziness tended to increase with increasing dosage of HCTZ and olmesartan medoxomil/HCTZ combination. None of the episodes of dizziness were judged by the investigator to be severe. Although upper respiratory tract infection was among the most frequently reported AE, it was not dose related and did not result in any discontinuations of therapy.
Although mean values for renal function tests (blood urea nitrogen [BUN] and serum creatinine) remained stable from baseline to the end of treatment, minor increases occurred more frequently in olmesartan medoxomil/HCTZ combination-treated patients than in those who received placebo or olmesartan medoxomil monotherapy. Because of the small number of patients in each treatment group, however, it is difficult to determine whether the increases in BUN or creatinine were due to study treatment. Increased BUN occurred in four subjects (two patients in each of the two highest olmesartan medoxomil dose groups in combination with HCTZ). Of these events, study investigators judged one to be possibly related to the study drug, one to be remotely related, and two as definitely not related. Only one patient (40 mg olmesartan medoxomil/25 mg HCTZ group) had a marked BUN abnormality (57 mg/dL), but this event was resolved with increased water intake and was judged by the investigator to be not clinically significant and definitely not related to the study HCTZ ϭ hydrochlorothiazide; LOCF ϭ last observation carried forward; SeDBP ϭ seated diastolic blood pressure; SeSBP ϭ seated systolic blood pressure. No adverse trends in liver enzyme levels were noted for any olmesartan medoxomil/HCTZ combination group, and no patient in an olmesartan medoxomil/HCTZ combination group discontinued the study because of elevation in aspartate aminotransferase or alanine aminotransferase. Electrolyte (sodium, potassium, bicarbonate, chloride, calcium, and phosphorus) mean values generally did not change during the study, although there was a slight decrease in the mean values of potassium in the olmesartan medoxomil/HCTZ combination groups. No cases of marked hypokalemia were observed, although a markedly elevated serum potassium of 5.9 mEq/L occurred in one patient in the 40 mg olmesartan medoxomil/25 mg HCTZ group, which was considered not to be clinically significant by the investigator.
Discussion
This study demonstrates that combination therapy with olmesartan medoxomil and HCTZ provides clinically meaningful antihypertensive effects. The greater antihypertensive efficacy of the olmesartan medoxomil/HCTZ combinations compared with that of the individual drugs was evident in a dose-dependent manner. All doses of olmesartan medoxomil/HCTZ combination therapy significantly decreased SeDBP and SeSBP compared with placebo. Evidence of efficacy for all active treatments was observed after 1 week of treatment, with further increases in efficacy reported throughout the course of the study. After 8 weeks of therapy, the proportion of patients with a BP response increased in a dose-dependent manner with Abbreviations as in Table 2 . olmesartan medoxomil alone, with HCTZ alone, and with combination therapy. Olmesartan medoxomil, both alone and in combination with HCTZ, was safe and well tolerated. The incidences of AEs, serious AEs, and discontinuations related to AEs were comparable among treatment groups and similar to the rates observed with placebo. The safety profile for olmesartan medoxomil/HCTZ was qualitatively similar to that reported for other ARB/HCTZ combinations. 29, 31 As with the safety and tolerability profile of olmesartan medoxomil monotherapy, there was no doseresponse relationship between the overall rates of AEs, serious AEs, and discontinuations because of AEs and increasing doses of olmesartan medoxomil/HCTZ combination therapy. The progressively declining incidence of headache observed with increasing dosages of combination therapy in this analysis is consistent with previous reports, which note that headache may be a feature of uncontrolled hypertension, and that safe and well tolerated antihypertensive therapies may result in a reduced incidence of headache. 32 Changes in laboratory values (BUN, creatinine, and uric acid) were not of clinical significance and were similar to the changes noted with other ARB/HCTZ combinations. 29, 31 Olmesartan medoxomil/HCTZ combination therapy is especially promising for patients in need of multiple agents to achieve their BP goal. Most hypertensive patients require combination therapy to attain the recommended goal BPs of Ͻ140/90 mm Hg for the general hypertensive population and Ͻ130/80 mm Hg for highrisk hypertensive patients such as those with diabetes or renal disease. [3] [4] [5] [6] [7] 33 Furthermore, the current view of effective management of hypertension relies on combining drugs with different but complementary mechanisms of action to obtain greater BP reductions. 3, 34, 35 The antihypertensive response to ARBs is potentiated in the presence of a negative salt balance. 36 By promoting salt elimination and stimulating the RAAS via intrarenal mechanisms, thiazide diuretics make BP more dependent on angiotensin II, thereby enhancing the antihypertensive efficacy of ARBs. 36, 37 In this study, the combination of the RAAS blocker olmesartan medoxomil with the diuretic HCTZ resulted in BP reductions of up to 26.8/21.9 mm Hg. Combinations of drugs with complementary mechanisms have the added benefit of allowing the use of lower doses of component drugs, thereby minimizing the risk of AEs and potentially enhancing patient compliance. [25] [26] [27] [28] 34, 35, 38 In conclusion, the combination of olmesartan medoxomil/HCTZ is a safe, well tolerated, and effective option for antihypertensive therapy, demonstrating greater BP reduction than monotherapy with either of its components. Antihypertensive efficacy of the combination of olmesartan medoxomil and HCTZ improved with increasing doses.
